Cargando…

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma

Primary liver cancer is one of the most common malignant tumors in China. The vast majority of primary liver cancer are hepatocellular carcinoma. Due to its high incidence and mortality from HCC, HCC has always been a feared type of cancer. Liver transplantation, as one of the important means to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Feng, Wang, Dawei, Huang, Lan, Jiang, Chun, Gao, Ce, Xiong, Cunquan, Zhai, Guanghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399574/
https://www.ncbi.nlm.nih.gov/pubmed/37545535
http://dx.doi.org/10.3389/fimmu.2023.1227756
_version_ 1785084271448293376
author Ju, Feng
Wang, Dawei
Huang, Lan
Jiang, Chun
Gao, Ce
Xiong, Cunquan
Zhai, Guanghua
author_facet Ju, Feng
Wang, Dawei
Huang, Lan
Jiang, Chun
Gao, Ce
Xiong, Cunquan
Zhai, Guanghua
author_sort Ju, Feng
collection PubMed
description Primary liver cancer is one of the most common malignant tumors in China. The vast majority of primary liver cancer are hepatocellular carcinoma. Due to its high incidence and mortality from HCC, HCC has always been a feared type of cancer. Liver transplantation, as one of the important means to treat advanced liver cancer, has brought new hope to patients. However, as patients have been in a state of immunosuppression after liver transplantation, these patients face new problems of HCC recurrence and metastasis. A increasing number of studies have proved that blocking the PD-1/PD-L1 signaling pathway and restoring the immune killing inhibition of T cells can produce better therapeutic effects on tumors and chronic infectious diseases. As a promising treatment in the field of tumor immunotherapy, PD-1/PD-L1 inhibitors have achieved important results in liver cancer patients, but their application in liver transplantation patients is still highly controversial. This paper will introduce the mechanism of action of PD-1/PD-L1 signaling pathway and the current basic and clinical studies of PD-1/PD-L1 signaling pathway associated with immune response in HCC transplantation.
format Online
Article
Text
id pubmed-10399574
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103995742023-08-04 Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma Ju, Feng Wang, Dawei Huang, Lan Jiang, Chun Gao, Ce Xiong, Cunquan Zhai, Guanghua Front Immunol Immunology Primary liver cancer is one of the most common malignant tumors in China. The vast majority of primary liver cancer are hepatocellular carcinoma. Due to its high incidence and mortality from HCC, HCC has always been a feared type of cancer. Liver transplantation, as one of the important means to treat advanced liver cancer, has brought new hope to patients. However, as patients have been in a state of immunosuppression after liver transplantation, these patients face new problems of HCC recurrence and metastasis. A increasing number of studies have proved that blocking the PD-1/PD-L1 signaling pathway and restoring the immune killing inhibition of T cells can produce better therapeutic effects on tumors and chronic infectious diseases. As a promising treatment in the field of tumor immunotherapy, PD-1/PD-L1 inhibitors have achieved important results in liver cancer patients, but their application in liver transplantation patients is still highly controversial. This paper will introduce the mechanism of action of PD-1/PD-L1 signaling pathway and the current basic and clinical studies of PD-1/PD-L1 signaling pathway associated with immune response in HCC transplantation. Frontiers Media S.A. 2023-07-20 /pmc/articles/PMC10399574/ /pubmed/37545535 http://dx.doi.org/10.3389/fimmu.2023.1227756 Text en Copyright © 2023 Ju, Wang, Huang, Jiang, Gao, Xiong and Zhai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ju, Feng
Wang, Dawei
Huang, Lan
Jiang, Chun
Gao, Ce
Xiong, Cunquan
Zhai, Guanghua
Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title_full Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title_fullStr Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title_full_unstemmed Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title_short Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
title_sort progress of pd-1/pd-l1 signaling in immune response to liver transplantation for hepatocellular carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399574/
https://www.ncbi.nlm.nih.gov/pubmed/37545535
http://dx.doi.org/10.3389/fimmu.2023.1227756
work_keys_str_mv AT jufeng progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT wangdawei progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT huanglan progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT jiangchun progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT gaoce progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT xiongcunquan progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma
AT zhaiguanghua progressofpd1pdl1signalinginimmuneresponsetolivertransplantationforhepatocellularcarcinoma